SCYNEXIS Net Cash Flow 2013-2025 | SCYX

SCYNEXIS net cash flow from 2013 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

SCYNEXIS Net Cash Flow 2013-2025 | SCYX

SCYNEXIS net cash flow from 2013 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$66B
Zoetis (ZTS)$65.7B
Daiichi Sankyo, - (DSNKY)$46.5B
Takeda Pharmaceutical (TAK)$45.7B
BeOne Medicines - (ONC)$32.7B
Sandoz Group AG (SDZNY)$27.5B
Summit Therapeutics (SMMT)$20.8B
Merck (MKKGY)$15.9B
Shionogi (SGIOY)$15.1B
United Therapeutics (UTHR)$13.5B
Neurocrine Biosciences (NBIX)$12.5B
IPSEN (IPSEY)$10.4B
Orion OYJ (ORINY)$10.3B
Madrigal Pharmaceuticals (MDGL)$7.6B
Corcept Therapeutics (CORT)$7.5B
Stevanato Group S.p.A (STVN)$7.3B
Grifols, S.A (GRFS)$7.3B
Ionis Pharmaceuticals (IONS)$6.5B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.2B
Hypermarcas (HYPMY)$2.7B
Crinetics Pharmaceuticals (CRNX)$2.6B
NewAmsterdam Pharma (NAMS)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.4B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B